Abstract
Serotonin (5-hydroxytryptamine; 5-HT) is a potent stimulator of aldosterone secretion in the rat adrenal gland but the type of receptor involved in the mechanism of action of 5-HT remains unknown. The aim of the present study was to determine the pharmacological profile and to clone the receptor responsible for the corticotropic effect of 5-HT in rat glomerulosa cells. A series of 10 serotonergic receptor agonists and 12 receptor antagonists was used to characterize the receptor mediating the effect of 5-HT on aldosterone secretion from perifused rat adrenocortical slices. Correlation analysis between the potencies of the different compounds in our model and those previously reported for various recombinant 5-HT receptors showed that the rat adrenal 5-HT receptor exhibits the same pharmacological profile as the 5-HT7 receptor transiently expressed in COS-7 cells (r = 0.82 for agonists, p < .05; r = 0.83 for antagonists,p < .01). Polymerase chain reaction with specific primers revealed the expression of 5-HT7 receptor mRNA in the rat adrenal gland. Cloning of the polymerase chain reaction product confirmed that the amplified DNA corresponded to the 5-HT7 receptor cDNA sequence. Western blot analysis showed the presence of a protein with an apparent molecular mass of 66 kDa in the adrenal cortex but not in the medulla. Taken together, these data demonstrate that the rat adrenal glomerulosa expresses functional 5-HT7 receptors. Rat glomerulosa cells will thus provide a robust and sensitive bioassay for future studies on native 5-HT7 receptors.
Footnotes
- Received January 20, 1999.
- Accepted May 26, 1999.
-
Send reprint requests to: Dr. Hubert Vaudry, European Institute for Peptide Research (IFRMP 23), Laboratory of Cellular and Molecular Neuroendocrinology, Institut National de la Sante et de la Recherche Medicale U413, Unité Associée Centre National de la Recherche Scientifique, University of Rouen, 76821 Mont-Saint-Aignan, France. E-mail:hubert.vaudry{at}univ-rouen.fr
-
This work was supported by grants from Institut National de la Santé et de la Recherche Médicale (U413) and the Conseil Régional de Haute-Normandie. S.L. was the recipient of a doctoral fellowship from the Conseil Régional de Haute-Normandie. L.G. was the recipient of a fellowship from the European Union (SOCRATES Program).
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
